Giotennis, the growth potential is incredible.
Yes, it will be interesting how they will react. What will they do if projections come in as Bloodhound99 stated:
"Calypte's sales projection for 2007 $ 4,593,000 as per last webcast.
I predict that when second quarter numbers are out on 8-15-2007 that they will still need more than $ 4,000,000 in remaining 6 months to meet their "PROJECTION"."
These numbers are solely derived from sales in Africa and the Middle East, which was stated to be coming in from Africa, in lots of 10,000 to 15,000 lots in quantity. Apparently, the revenue of the orders flowing in were averaged to come to the conclusion of the projection.
And, as Bloodhound stated, there are STILL THREE MORE QUARTERS to be reported this year.
In 2006, there was $307,000 in sales of the Aware Test
In 2007, they project $3,368,000 in sales of the Aware Test.
In 2008, they project $13,474,000 in sales of the Aware Test.
In 2006, there was $241,000 in sales of the Bed Incidence Test
In 2007, they project $1,225,000 in sales of the Bed Incidence Test
In 2008, they project $1,529,000 in sales of the Bed Incidence Test.
Clearly, with the figured projections for 2007, there has to be significant activity with orders and sales from the UAE and the African countries. Roger Gale did state that African orders were rapidly ramping and there were orders being received in 10,000 to 15,000 lot quantities.
The 2008 figure is not an unreasonable figure considering the population of India and the recent approval of the test. In comparison, in the U.S. market, Orasure, with an inferior test, has made over $8 million dollars in all their markets with that test alone.
Therefore, the figures are not unrealistic, especially with the large population countries which Calypte is approved and pending approval. Its phenomenal growth, especially in the limited amount of time since the initial approvals.
News 
Market Data 
Discover 
AI
